11月28日，中国医药研发服务商康龙化成于港交所上市，此次上市共筹集约46亿港元（约5.88亿美元）资金。中伦律师事务所担任了发行人中国律师，美迈斯律师事务所担任其香港及美国法律师。君合律师事务所及世达国际律师事务所为联席保荐人提供了法律意见。

根据君合的一份新闻稿，康龙化成成立于2004年，总部设于北京，目前是中国第二大医药研发服务平台及全球三大药物发现服务供应商之一。目前，康龙化成的客户覆盖全球排名前二十的跨国制药企业，其中包括阿斯利康、默沙东、强生、拜耳等。

中伦团队此次牵头合伙人为胡廷锋和王川；美迈斯团队牵头人为合伙人顾静玉、朱柯和郭伟炎；君合团队牵头律师为合伙人王毅，主办合伙人为孙小佳；世达团队的牵头律师为合伙人高准和王鹏。

担任此次发行联席保荐人的是高盛、中信里昂证券，以及东方融资。

Zhong Lun, OMM, JunHe, Skadden act on Pharmaron's $589 mln HK IPO

Zhong Lun Law Firm and O’Melveny & Myers have advised Chinese drug development service provider Pharmaron on its $588 million Hong Kong initial public offering, with JunHe and Skadden, Arps, Slate, Meagher & Flom advising the joint sponsors.

According to a press release, Pharmaron, based in Beijing and founded in 2004,  is a fully integrated pharmaceutical Research & Development platform serving China and overseas pharmaceutical companies, assisting on drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.

The Zhonglun team was led by partners Hu Tingfeng and Wang Chuan; the OMM team was led by partners Portia Ku, Zhu Ke and Edwin Kwok; the JunHe team was led by partner Wang Yi, with assistance from partner Sun Xiaojia; and the Skadden team was led by partners Julie Gao and Paloma Wang.

The Joint Sponsors are Goldman Sachs, CLSA and Orient Capital.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.